Skip to content

Opioid maintenance and neuropsychologic performance

Opioid maintenance and neuropsychologic performance

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037636
Enrollment
60
Registered
2025-08-14
Start date
2001-02-19
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F11.2

Interventions

Group 1: Opioid-dependent patients
new admissions to opioid agonist treatment (OAT) with intravenously administered diacetylmorphine (IV-DAM). The participants will complete the Symptom-Checklist (SCL-90-R), the Beck-Depressions-Invent
new admissions to opioid agonist treatment with oral medication (PO-OAT). The participants will complete the Symptom-Checklist (SCL-90-R), the Beck-Depressions-Inventar (BDI), and a computerised neuro

Sponsors

Psychiatrische Universitätsklinik Zürich
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 45 Years

Inclusion criteria

Inclusion criteria: -Opioid dependence nach ICD-10 -German (Swiss-German) mother tongue -Provided written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: - any history of severe cerebral trauma; - any medical condition deemed clinically significant for the integrity of neurocognitive functioning - any present co-occurring serious mental health illness other than substance dependence

Design outcomes

Primary

MeasureTime frame
- Whether opioid-dependent patients show neuropsychological deficits related to their drug use history prior to admission to OAT (baseline). - Whether IV-DAM or PO-OAT influence performance on neuropsychological tests. - Whether there are differences between IV-DAM and PO-OAT in terms of performance on neuropsychological tests. The participants will complete the Symptom-Checklist (SCL-90-R), the Beck-Depressions-Inventar (BDI), and a computerised neuropsychological test-battery before starting OAT (baseline) and 12 weeks later (follow-up). At follow-up the neuropsychological assessment will be carried out two hours after the opioid administration. The neuropsychological battery, which was established to assess cognitive impairment, will include the following tests: •Mehrfachwahl-Wortschatztest [MWT]: premorbid verbal intelligence •Rey-Osterrieth Complex Figure Test [RCFT] and Taylors Complex Figure Test at follow-up: verbal memory and visuo-perceptual functioning •Rey Auditory Verbal Learning Test [RAVLT]: immediate and delayed verbal recall •Rey Visual Design Learning Test [RVDLT]: immediate and delayed visual recall •S-Wörter nach Thurstone: verbal fluency, spontaneous productivity of language, adaptive flexibility •Farbe-Wort-Interferenz-Test nach Stroop [FWIT]: suppression of verbal interference •5 Punkte-Test nach Regard: adaptive flexibility, spontaneous figurative productivity •Assoziationslernen nach Goldenberg: figural-visual adaptive flexibility •Test d2 - Aufmerksamkeits-Belastungs-Test: selective attention •Zahlen-Symbol-Test [ZST]: sustained attention, general perceptuo-motor speed •Zahlen-Nachsprechen [Digit Span]: working memory, immediate recall Intra- and intergroup-comparisons will be made with regard to the results of the neuropsychological test performances.

Secondary

MeasureTime frame
- Whether dosage, frequency of opioid administration, or concomitant use of street drugs have an effect on the neuropsychological test performance.

Countries

Switzerland

Contacts

Public ContactKenneth Dürsteler

Universitäre Psychiatrische Kliniken Basel

kenneth.duersteler@upk.ch+41 61 325 5125

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026